Literature DB >> 18057440

Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate.

Ralph K H Cheung1, K K Leung, K C Lee, T C Chow.   

Abstract

Fractures associated with osteoporosis are common among elderly people and postmenopausal women. Bisphosphonate is an effective anti-resorptive drug commonly used for the prevention and treatment of osteoporosis. There are, however, concerns about potential side-effects during long-term treatment with alendronate. We report a case where an 82-year-old woman who had been taking alendronate for 10 years presented with two episodes of non-traumatic femoral shaft fracture. An iliac bone biopsy showed severely suppressed bone turnover, suggestive of adynamic bone disease. We suspect the bone turnover suppression was related to the prolonged use of alendronate.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18057440

Source DB:  PubMed          Journal:  Hong Kong Med J        ISSN: 1024-2708            Impact factor:   2.227


  20 in total

Review 1.  Update in women's health for the general internist.

Authors:  Judith M E Walsh; Megan McNamara; Redonda G Miller; Eleanor Bimla Schwarz
Journal:  J Gen Intern Med       Date:  2011-10-13       Impact factor: 5.128

2.  Factors Associated with Increased Healing Time in Complete Femoral Fractures After Long-Term Bisphosphonate Therapy.

Authors:  Hae-Seong Lim; Chong-Kwan Kim; Youn-Soo Park; Young-Wan Moon; Seung-Jae Lim; Sang-Min Kim
Journal:  J Bone Joint Surg Am       Date:  2016-12-07       Impact factor: 5.284

Review 3.  Review: epidemiology and pathophysiology of atypical femur fractures.

Authors:  Alvin C Ng; Meng Ai Png; David T Chua; Joyce S B Koh; Tet Sen Howe
Journal:  Curr Osteoporos Rep       Date:  2014-03       Impact factor: 5.096

Review 4.  Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates.

Authors:  Jeri W Nieves; Felicia Cosman
Journal:  Curr Osteoporos Rep       Date:  2010-03       Impact factor: 5.096

5.  Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series.

Authors:  Satoshi Sasaki; Naohisa Miyakoshi; Michio Hongo; Yuji Kasukawa; Yoichi Shimada
Journal:  J Bone Miner Metab       Date:  2012-05-19       Impact factor: 2.626

6.  Atypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates.

Authors:  Frankie Leung; Tak-Wing Lau; Michael To; Keith Dip-Kei Luk; Annie Wai Chee Kung
Journal:  BMJ Case Rep       Date:  2009-03-05

7.  Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.

Authors:  G Bianchi; E Czerwinski; A Kenwright; A Burdeska; R R Recker; D Felsenberg
Journal:  Osteoporos Int       Date:  2012-06       Impact factor: 4.507

Review 8.  Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.

Authors:  Beatrice J Edwards; Andrew D Bunta; Joseph Lane; Clarita Odvina; D Sudhaker Rao; Dennis W Raisch; June M McKoy; Imran Omar; Steven M Belknap; Vishvas Garg; Allison J Hahr; Athena T Samaras; Matthew J Fisher; Dennis P West; Craig B Langman; Paula H Stern
Journal:  J Bone Joint Surg Am       Date:  2013-02-20       Impact factor: 5.284

9.  Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk.

Authors:  David B Burr; Tamim Diab; Andrew Koivunemi; Mark Koivunemi; Matthew R Allen
Journal:  J Orthop Res       Date:  2009-10       Impact factor: 3.494

10.  Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital.

Authors:  Kuntheavy Ing-Lorenzini; Jules Desmeules; Olivier Plachta; Domizio Suva; Pierre Dayer; Robin Peter
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.